Jan 20, 2020 | CancerIQ
CHICAGO, January 20, 2020 — Feyi Olopade Ayodele, co-founder and CEO of CancerIQ, will present at the 2020 Annual Meeting of the Association of Cancer Executives next week. Ayodele will share best practices for a data-driven approach to building and scaling genetic risk assessment programs in all care settings.
The ACE committee welcomed Ayodele — a thought leader in the world of genomics and risk assessment — to present at the 2020 conference after a compelling presentation in 2019 from a CancerIQ client.
Under Ayodele’s leadership, CancerIQ has demonstrated success in implementing genetic counseling and testing in cancer and non-cancer programs across diverse clinical settings and varying technology infrastructures.
In this year’s presentation at ACE, Ayodele will share how CancerIQ has helped providers increase screening rates, increase service capacity, and create new revenue opportunities. Specifically, attendees will learn how to start and grow a program, increase capacity for genetic specialists, consider the financials, and get leadership buy-in.
“I’m excited to share how our clients have significantly increased access to genetic counseling and testing among patients in all care settings,” Ayodele said. “ACE attendees truly share our commitment to finding data-driven ways to predict, preempt and prevent cancer across all populations. I look forward to connecting with everyone again this year.”
Ayodele will present on “Improving Access to Genetic Counseling and Testing” to kick-off pre-conference Workshop #3 on Wednesday, Jan. 22 from 1:15-2:30 p.m. Click here if you wish to learn more about this Workshop or would like to schedule a meet-up at the conference.
CancerIQ's technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and — most importantly — improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at canceriq.com.